Clinical Trial

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate safety, tolerability, PK and immunogenicity of SV001 compare to placebo in Chinese healthy adult volunteers.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-18; most recent amendment 2026-03-09.
Trial Details
NCT Number NCT06267183
Lead Sponsor Shanghai Synvida Biotechnology Co.,Ltd.
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 53 participants
Start Date 2024-01-12
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14